Effective prison-based treatment and linkage to care after release
Timothy J Papaluca, George Tambakis, David Iser, Alexander J Thompson
The Lancet Infectious Diseases | ELSEVIER SCI LTD | Published : 2019
Awarded by NHMRC
TJP has received honoraria from Merck Sharp & Dohme. GT declares no competing interests. DI has received honoraria from AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Gilead, and Eisai. AJT has received investigator-initiated research funding to their institution from Gilead, Merck Sharpe & Dohme, AbbVie, and Bristol-Myers Squibb, and has been an advisory board member for Gilead, AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Eisai and Bayer. AJT has received funding from the National Health and Medical Research Council of Australia (Practitioner Fellowship 1142976). This work was supported by NHMRC Partnership grant 1116161 and NHMRC Program grant 1132902.